small molecule

VEPPANU

VEPDEGESTRANT

Loss of exclusivityJanuary 2038latest FDA-listed patent expiry

CompanyARVINAS OPERATIONS INC

Drug detail

Brand name	VEPPANU
Active ingredient	VEPDEGESTRANT
Strength	100MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
10647698	January 2038	substance, product
11597720	December 2037	substance, product
10899742	December 2037	use U-4278

Regulatory exclusivity

Code	Expires
NCE	May 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from ARVINAS OPERATIONS INC